Navega Therapeutics is a preclinical stage company developing fully human epigenetic modulators for neurological and ophthalmic diseases. Our zinc finger technology is founded on compatibility of adjacent zinc fingers instead of modularity, achieving higher specificity and efficacy. We have also established the first AI driven design model to target any sequence in the human genome with the same ease as designing a gRNA. In addition, we have developed proprietary fully human repressors and activators.
Our lead program is a gene therapy to treat chronic pain and tackle the opioid epidemic. We have achieved pain relief in three preclinical pain models via repression of Nav1.7, a pain gatekeeper gene. Our approach is completely different from previous failed attempts. Instead of targeting the protein, or the RNA which undergoes extensive turnover, we saw the advantage of targeting the DNA of Nav1.7 to downregulate the channel without introducing permanent mutations.
Our lead program is a gene therapy to treat chronic pain and tackle the opioid epidemic. We have achieved pain relief in three preclinical pain models via repression of Nav1.7, a pain gatekeeper gene. Our approach is completely different from previous failed attempts. Instead of targeting the protein, or the RNA which undergoes extensive turnover, we saw the advantage of targeting the DNA of Nav1.7 to downregulate the channel without introducing permanent mutations.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Nav1.7
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
